Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer

Akhil Chawla; Tiffany L. Huang; Andrew M. Ibrahim; Jeffrey M. Hardacre; Christopher Siegel; John B. Ammori

doi:10.1016/j.hpb.2017.10.011

Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer

Akhil Chawla, Tiffany L. Huang, Andrew M. Ibrahim, Jeffrey M. Hardacre, Christopher Siegel, John B. Ammori^*

^*Corresponding author for this work

Robert H. Lurie Comprehensive Cancer Center

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Background: Pretherapy serum neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have both been identified as prognostic in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to identify the prognostic implication of pretherapy NLR and PLR in patients with resectable PDAC. Methods: Data were collected retrospectively on patients operated at our institution between 2004 and 2014. A Cox proportional hazards model was used to investigate the relationship between clinical and pathological parameters, NLR and PLR to overall survival (OS). Survival data were analyzed using the Kaplan–Meier method. Results: 217 patients were analyzed with a median overall survival (OS) of 17.5 months. Factors identified as being predictive of OS by univariate analysis included age, receipt of adjuvant therapy, margin positivity, pathologic angiolymphatic invasion, T-stage, and N-stage (P < 0.05). Factors identified as being independently predictive of OS by multivariate analysis included age and angiolymphatic invasion (P < 0.05). NLR and PLR were not predictive of OS. Survival analysis demonstrated no difference in OS in patients who had high or low NLR or PLR. Discussion: Pretherapy NLR and PLR do not predict survival in patients who underwent pancreatectomy for PDAC at our institution.

Original language	English (US)
Pages (from-to)	398-404
Number of pages	7
Journal	HPB
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/j.hpb.2017.10.011
State	Published - May 2018

ASJC Scopus subject areas

Gastroenterology
Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hpb.2017.10.011

Cite this

@article{2ec42ae22c9e41f691b454a438d5d9fe,

title = "Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer",

abstract = "Background: Pretherapy serum neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have both been identified as prognostic in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to identify the prognostic implication of pretherapy NLR and PLR in patients with resectable PDAC. Methods: Data were collected retrospectively on patients operated at our institution between 2004 and 2014. A Cox proportional hazards model was used to investigate the relationship between clinical and pathological parameters, NLR and PLR to overall survival (OS). Survival data were analyzed using the Kaplan–Meier method. Results: 217 patients were analyzed with a median overall survival (OS) of 17.5 months. Factors identified as being predictive of OS by univariate analysis included age, receipt of adjuvant therapy, margin positivity, pathologic angiolymphatic invasion, T-stage, and N-stage (P < 0.05). Factors identified as being independently predictive of OS by multivariate analysis included age and angiolymphatic invasion (P < 0.05). NLR and PLR were not predictive of OS. Survival analysis demonstrated no difference in OS in patients who had high or low NLR or PLR. Discussion: Pretherapy NLR and PLR do not predict survival in patients who underwent pancreatectomy for PDAC at our institution.",

author = "Akhil Chawla and Huang, {Tiffany L.} and Ibrahim, {Andrew M.} and Hardacre, {Jeffrey M.} and Christopher Siegel and Ammori, {John B.}",

note = "Publisher Copyright: {\textcopyright} 2017 International Hepato-Pancreato-Biliary Association Inc.",

year = "2018",

month = may,

doi = "10.1016/j.hpb.2017.10.011",

language = "English (US)",

volume = "20",

pages = "398--404",

journal = "HPB",

issn = "1365-182X",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer

AU - Chawla, Akhil

AU - Huang, Tiffany L.

AU - Ibrahim, Andrew M.

AU - Hardacre, Jeffrey M.

AU - Siegel, Christopher

AU - Ammori, John B.

PY - 2018/5

Y1 - 2018/5

N2 - Background: Pretherapy serum neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have both been identified as prognostic in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to identify the prognostic implication of pretherapy NLR and PLR in patients with resectable PDAC. Methods: Data were collected retrospectively on patients operated at our institution between 2004 and 2014. A Cox proportional hazards model was used to investigate the relationship between clinical and pathological parameters, NLR and PLR to overall survival (OS). Survival data were analyzed using the Kaplan–Meier method. Results: 217 patients were analyzed with a median overall survival (OS) of 17.5 months. Factors identified as being predictive of OS by univariate analysis included age, receipt of adjuvant therapy, margin positivity, pathologic angiolymphatic invasion, T-stage, and N-stage (P < 0.05). Factors identified as being independently predictive of OS by multivariate analysis included age and angiolymphatic invasion (P < 0.05). NLR and PLR were not predictive of OS. Survival analysis demonstrated no difference in OS in patients who had high or low NLR or PLR. Discussion: Pretherapy NLR and PLR do not predict survival in patients who underwent pancreatectomy for PDAC at our institution.

AB - Background: Pretherapy serum neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have both been identified as prognostic in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to identify the prognostic implication of pretherapy NLR and PLR in patients with resectable PDAC. Methods: Data were collected retrospectively on patients operated at our institution between 2004 and 2014. A Cox proportional hazards model was used to investigate the relationship between clinical and pathological parameters, NLR and PLR to overall survival (OS). Survival data were analyzed using the Kaplan–Meier method. Results: 217 patients were analyzed with a median overall survival (OS) of 17.5 months. Factors identified as being predictive of OS by univariate analysis included age, receipt of adjuvant therapy, margin positivity, pathologic angiolymphatic invasion, T-stage, and N-stage (P < 0.05). Factors identified as being independently predictive of OS by multivariate analysis included age and angiolymphatic invasion (P < 0.05). NLR and PLR were not predictive of OS. Survival analysis demonstrated no difference in OS in patients who had high or low NLR or PLR. Discussion: Pretherapy NLR and PLR do not predict survival in patients who underwent pancreatectomy for PDAC at our institution.

UR - http://www.scopus.com/inward/record.url?scp=85037035664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037035664&partnerID=8YFLogxK

U2 - 10.1016/j.hpb.2017.10.011

DO - 10.1016/j.hpb.2017.10.011

M3 - Article

C2 - 29221789

AN - SCOPUS:85037035664

SN - 1365-182X

VL - 20

SP - 398

EP - 404

JO - HPB

JF - HPB

IS - 5

ER -

Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this